

Acute to long-term characteristics of impedance recordings during neurostimulation in humans

Jie Cui, PhD^{1,2,3} (E-mail: cui.jie@mayo.edu, ORCID: 0000-0003-1000-8869)

Filip Mivalt, MS^{1,4,5} (E-mail: Mivalt.Filip@mayo.edu, ORCID: 0000-0002-0693-9495)

Vladimir Sladky^{1,5,6} (E-mail: Sladky.Vladimir@mayo.edu, ORCID: 0000-0002-4712-7039)

Jiwon Kim¹ (E-mail: Kim.Jiwon@mayo.edu)

Thomas J. Richner, PhD¹ (E-mail: Richner.Thomas@mayo.edu)

Brian N. Lundstrom, MD PhD¹ (E-mail: Lundstrom.Brian@mayo.edu, ORCID: 0000-0002-5310-5549)

Jamie J. Van Gompel, MD⁷ (E-mail: VanGompel.Jamie@mayo.edu, ORCID: 0000-0001-8087-7870)

Hai-long Wang, PhD¹ (E-mail: hwang@mayo.edu, ORCID: 0000-0001-9013-3007)

Kai J. Miller, MD PhD⁷ (E-mail: Miller.Kai@mayo.edu)

Nicholas Gregg, MD¹ (E-mail: Gregg.Nicholas@mayo.edu, ORCID: 0000-0002-6151-043X)

Long Jun Wu, PhD¹ (E-mail: wu.longjun@mayo.edu, ORCID: 0000-0001-8019-3380)

Timothy Denison, PhD⁸ (E-mail: timothy.denison@bndu.ox.ac.uk, ORCID: 0000-0002-5404-4004)

Bailey Winter, MS^{1,3} (E-mail: Winter.Bailey@mayo.edu, ORCID: 0000-0003-1157-2138)

Benjamin H. Brinkmann, PhD^{1,2} (E-mail: Brinkmann.Benjamin@mayo.edu, ORCID: 0000-0002-2392-8608)

Vaclav Kremen, MS PhD^{1,9} (E-mail: Kremen.Vaclav@mayo.edu, ORCID: 0000-0001-9844-7617)

Gregory A. Worrell, MD PhD^{1,2} ✉ (E-mail: Worrell.Gregory@mayo.edu, ORCID: 0000-0003-2916-0553)

¹Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA

²Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA

³Mayo College of Medicine and Science, Mayo Clinic, Rochester, Minnesota, USA

⁴Department of Biomedical Engineering, Faculty of Electrical Engineering and Communication, Brno University of Technology, Brno, Czech Republic

⁵International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic

⁶Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic

⁷Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA

⁸Department of Engineering Science, University of Oxford; MRC Brain Network Dynamics Unit, University of Oxford, OX3 7DQ UK

1 ⁹Czech Institute of Informatics, Robotics, and Cybernetics, Czech Technical University, Prague,
2 Czech Republic

3

4 Corresponding Author:

5 Gregory A. Worrell MD PhD

6 Professor of Neurology and Biomedical Engineering

7 Consultant, Neurology

8 Mayo Clinic, Rochester, MN 55905

9 E-Mail: Worrell.Gregory@mayo.edu

10

1 Abstract

2 **Objective:** This study aims to characterize the time course of impedance, a crucial
3 electrophysiological property of brain tissue, in the human thalamus (THL), amygdala-
4 hippocampus (AMG-HPC), and posterior hippocampus (post-HPC) over an extended period.

5 **Approach:** Impedance was periodically sampled every 5-15 minutes over several months in five
6 subjects with drug-resistant epilepsy using an experimental neuromodulation device. Initially, we
7 employed descriptive piecewise and continuous mathematical models to characterize the
8 impedance response for approximately three weeks post-electrode implantation. We then explored
9 the temporal dynamics of impedance during periods when electrical stimulation was temporarily
10 halted, observing a monotonic increase (rebound) in impedance before it stabilized at a higher
11 value. Lastly, we assessed the stability of amplitude and phase over the 24-hour impedance cycle
12 throughout the multi-month recording.

13 **Main results:** Immediately post-implantation, the impedance decreased, reaching a minimum
14 value in all brain regions within approximately two days, and then increased monotonically over
15 about 14 days to a stable value. The models accounted for the variance in short-term impedance
16 changes. Notably, the minimum impedance of the THL in the most epileptogenic hemisphere was
17 significantly lower than in other regions. During the gaps in electrical stimulation, the impedance
18 rebound decreased over time and stabilized around 200 days post-implant, likely indicative of the
19 foreign body response and fibrous tissue encapsulation around the electrodes. The amplitude and
20 phase of the 24-hour impedance oscillation remained stable throughout the multi-month recording,
21 with circadian variation in impedance dominating the long-term measures.

1 **Significance:** Our findings illustrate the complex temporal dynamics of impedance in implanted
2 electrodes and the impact of electrical stimulation. We discuss these dynamics in the context of
3 the known biological foreign body response of the brain to implanted electrodes. The data suggest
4 that the temporal dynamics of impedance are dependent on the anatomical location and tissue
5 epileptogenicity. These insights may offer additional guidance for the delivery of therapeutic
6 stimulation at various time points post-implantation for neuromodulation therapy.

7 **Keywords**

8 Biological impedance, Neuromodulation, Implant effect, Intracranial monitoring, Circadian cycle,
9 Epilepsy

10

11

1 Introduction

2 Implantable neural sensing and stimulation (INSS) devices, which are capable of closed-loop
3 therapy based on continuous monitoring of brain local field potentials and automated brain state
4 classifications, enable adaptive long-term neural modulation [1-5]. Thus, the stability of the
5 electrode-tissue interface is needed for optimal maintenance of accurate automated brain-state
6 classifications, such as sleep and seizure, and optimal neuromodulation therapy over long periods
7 (months to years) [6-8]. Instability of the electrode-tissue interface and associated electrical
8 impedance may compromise the quality of electrophysiological recordings, brain-state
9 classification, and the delivery of appropriate therapy.

10 Electrode impedance is widely used to assess the quality and stability of neural sensing and
11 stimulation [9]. Changes in electrical interface impedance are generally assumed to stabilize
12 multiple weeks after implantation [10, 11]. Impedance determines the local field potential (LFP)
13 characteristics [12], which have been used in automated brain-state classifications, and drives the
14 voltage-current relationship of therapeutic electrical stimulation. Impedance measurements can
15 be conveniently performed using sensing and stimulation electrodes. Impedance changes provide
16 insights into time-varying factors related to devices and tissues but may indicate problems with
17 the electrode or electrode-tissue interface [7]. Although short-term changes in electrical
18 impedance post-implant are well documented [7, 13], reports of long-term impedance
19 measurements in humans are sparse [6] and relatively little is known about the chronic
20 characteristics of impedance in the human limbic system [14, 15]. However, this information is
21 necessary for evaluation and optimal tracking of biomarkers and delivery of therapeutic
22 stimulation [2].

1 In addition to its role in interrogating INSS, electrical impedance is useful for characterizing brain
2 neurophysiology [15]. For instance, in the central nervous system (CNS), increased impedance is
3 correlated with decreased extracellular space (ECS) [16-18], modified electric field potential
4 propagation [12], increased seizure activities [19, 20], and behavioral state changes [8, 18, 21-23].
5 In this study, we analyzed long-term impedance recordings from five patients with drug-resistant
6 epilepsy implanted with investigational INSS devices [2]. The electrical impedance was measured
7 periodically, as described in the Methods section. We investigated acute (1 – 3 days), subacute (4
8 days to 3 weeks post-implant), and long-term (> 3 weeks) two-point impedance measurements
9 from multiple brain regions. We compared a piecewise and continuous mathematical model to
10 capture the initial drop and later recovery phases of acute and subacute impedance dynamics.
11 We analyzed impedance changes during *gaps* in therapeutic stimulation. Previous studies have
12 indicated that repeated voltage biasing can reduce electrode-tissue impedance [24]. Therefore,
13 measuring impedance change during brief pauses in therapeutic electrical stimulation can provide
14 insights into impedance change at electrode-tissue interface.
15 Finally, we described long-term amplitude and phase of 24-hour¹ cycle of impedance [23].
16 Spectral analysis of impedance timeseries revealed strong oscillations around the periodicity of
17 24.01 ± 0.39 hour, consistent with previously observed extracellular volume changes in rodent
18 glymphatic system [18]. We thus analyzed the long-term characteristics of the impedance cycle
19 as indicators of their stability.

20

¹ In this paper, the term “24-hour cycle” is used interchangeably with “circadian cycle”.

1 Methods

2 **Subjects and data acquisition**

3 Subject recruitment, INSS implantation, and electrical impedance measurements were performed
4 as previously described [2, 23]. Briefly, five human subjects (S1 – S5) with drug-resistant bilateral
5 mesial temporal lobe epilepsy were implanted with investigational Medtronic Summit RC+S™
6 devices (Medtronic, Minnesota, USA) targeting the bilateral anterior nucleus of the thalamus and
7 bilateral mesial temporal structures. While the patients had bilateral mesial temporal lobe epilepsy,
8 it is important to note that the left hemisphere was the most epileptogenic, with most seizures and
9 interictal epileptiform activity (Table 1). Each patient was implanted with four leads with four
10 electrodes (contacts) per lead (16 channels per patient); leads were implanted in the left and right
11 thalamus (THL), amygdala-hippocampus (AMG-HPC), and posterior hippocampus (post-HPC),
12 except for S2, whose left AMG-HPC was partially resected from a prior anterior temporal
13 lobectomy.

14 Platinum-Iridium (Pt-Ir) alloy contacts were used, owing to their low impedance, electrochemical
15 stability, excellent biocompatibility, corrosion resistance, and radiopacity. They are widely used
16 as implanted pial cortical and parenchymal electrodes for electrical brain stimulation (continuous,
17 duty cycle, and responsive stimulation) with charge-balanced, asymmetrical biphasic Lily pulse
18 waveforms over a wide range of frequencies (~2 – 145 Hz) within established safe charge densities
19 ($< 30 \mu\text{C}/\text{cm}^2$). Two types of leads were implanted, with Medtronic 3387 leads (span 10.5 mm
20 with four 1.5 mm long and 1.27 mm diameter contacts, surface area = 5.985 mm^2 , separated by
21 1.5 mm) targeting bilateral THL areas and Medtronic 3391 leads (spans 14.5 mm with four 3 mm
22 long and 1.27 mm diameter contacts, surface area = 11.97 mm^2 , separated by 4 mm) targeting

1 bilateral AMG-HPC and post-HPC areas. A longer span of Medtronic 3391 lead was used along
2 the long axis of the AMG-HPC complex.

3 Electrical two-point monopolar measurements were nonuniformly sampled in these five subjects
4 and streamed to the cloud database through a wireless network [2, 25]. The impedance
5 measurement methods are detailed previously [23] and a brief description is provided in Figure 1.
6 The monopolar impedances were sampled from the 16 electrode contacts using the RC+S™ device
7 as the monopolar current return for using a single square-wave current pulse (0.4 mA, 80 μs pulse
8 width). The voltage (V) was measured at 70 μs near the end of the injected pulse (I), and the
9 effective impedance (Z) was calculated as $Z = V/I$ following Ohm's law. Our benchtop
10 experiments show that this effective impedance is equivalent to an impedance measured by
11 injecting a 1 kHz sinusoidal current with an amplitude of 500 nA, insensitive to the electrode-
12 tissue (or electrode-electrolyte) interface impedance. Current stimulation and sensing voltage
13 values were delivered using the same electrodes, while therapeutic stimulation was delivered only
14 via 3387 leads targeting the THL (two per hemisphere).

15 The impedance sampling schemes varied among the subjects. For S1, impedance was sampled
16 approximately once per day for the first 128 days post-implant and then about once per 15 min for
17 the rest of the recordings. For S2, it was sampled about once per 15 min for the first 3 weeks and
18 then every 5 – 15 min. For S3, one impedance value was measured every 15 min throughout the
19 recordings. S4 did not have impedance measurements for the first 9 days and then it was sampled
20 at about one sample per 15 min. For S5, the impedance was sampled at about every 5 min
21 throughout the recordings. Larger intermittent intervals without impedance measurements existed
22 in the recordings related to the loss of wireless connectivity.

1 Note that for the analysis of acute and subacute impedance changes, S4 was excluded due to the
2 absence of impedance in the first 9 days post-implant. For the analyses of impedance in gaps of
3 therapeutic stimulation and long-term stability of 24-hour cycles, S5 was excluded because no gap
4 exists in the recordings and S5 does not have adequate data for long-term analysis. Additionally,
5 for the analysis of long-term stability, the first 128-day recording of S1 was excluded due to the
6 low sampling rate, and no analysis of S3 was presented for the left AMG-HPC due to prior
7 resection of the anterior temporal lobectomy.

8 All activities were approved by Mayo Clinic IRB:18-005483 ‘Human Safety and Feasibility Study
9 of Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy,’ and all
10 subjects provided informed consent.

11 **Characterization of acute and subacute impedance change**

12 To characterize the initial dynamics of Z after implantation, we proposed a piecewise function
13 model consisting of parabolic and exponential functions:

$$Z(t) = \begin{cases} a_1^2(t - t_1)^2 + c_1 & \text{for } t < t_0 \\ -a_2 e^{-(t-t_2)/\tau} + c_2 & \text{for } t \geq t_0, \end{cases} \quad (1)$$

14 where the model parameters $a_1, a_2, t_1, t_2, c_1, c_2, \tau, t_0 \in \mathbb{R}^+$. The initial decrease and subsequent
15 increase in effective impedance were modeled by the parabolic function, while the subsequent
16 recovery of impedance until a relatively stable level was described by the exponential function.
17 Node t_0 indicates the time boundary of the two functions. Here, the time constant τ characterizes
18 the rate of the impedance change after t_0 . A more intuitive measure is the half-life, $t_{1/2} = \tau \ln(2)$,
19 which is the time elapsed from $t = t_0$ to the instant when Z arrives at the midway point to the

1 asymptotic value c_2 , that is, $Z(t_{1/2}) = \frac{1}{2}[Z(t_0) + c_2]$. Model parameters were estimated using a
2 nonlinear least-squares algorithm (Appendix A).

3 By assuming that the impedance reaches the steady state when the first-order derivative of the
4 exponential function is smaller than a threshold α , the start time, $t_\alpha > t_0$, of stable Z can be
5 determined as follows (Appendix A):

$$t_\alpha \geq b_2 + \tau \ln\left(\frac{a_2}{\alpha\tau}\right). \quad (2)$$

6 The suggested empirical model is descriptive rather than derived from fundamental physiological
7 mechanisms, and thus may not be unique in characterizing the data. Therefore, we explored an
8 alternative model of double exponentials given by

$$f(t) = a_1 e^{-(t-t_1)/\tau_1} + a_2(1 - e^{-(t-t_2)/\tau_2}) + c. \quad (3)$$

9 Setting $t_1 = t_2 = c = 0$ results in a four-parameter equation:

$$f(t) = a_1 e^{-t/\tau_1} + a_2(1 - e^{-t/\tau_2}). \quad (4)$$

10 This model is continuous and has less degree of freedom. Figure 2C shows the comparison of the
11 fittings of the two models to the raw impedance data. However, the piecewise model acquires a
12 higher capability of explaining the variance in the data.

13 **Characterizing Z in gaps of therapeutic stimulation**

14 Impedance changes during gaps in therapeutic stimulation provide a means to investigate the
15 properties of electrode-tissues interface and bulk tissue close to the electrode. We define a gap as
16 the time interval when the amplitude of the electrical current stimulation signal is set to zero. The
17 timing and duration of the gaps varied within and across subjects, as the temporary cessation of

1 stimulation was in accordance with each patient’s clinical needs. To select valid gaps for
2 subsequent characterization, we applied two criteria: (1) the gaps were at least 3 weeks (i.e., 21
3 days) after the implantation of the RC+S™ device, and (2) at least four impedance values were
4 measured in a gap for reliable fitting of an exponential function (described below).

5 For each valid gap, we quantified the impedance change relative to the impedance before the
6 stimulation was turned *off* and the half-life ($t_{1/2}$) of the fitted exponential function. We refer to a
7 unique combination of amplitude, frequency, and pulse width of stimulation as a single state of
8 stimulation. We found the median impedance during the gap and the stimulation state immediately
9 before the gap and calculated the relative impedance change as the difference between these two
10 medians. Additionally, we estimated the half-life of the impedance change by fitting a single
11 exponential (not the piecewise model shown in Section Characterization of acute and subacute
12 impedance change) in a gap. Because the impedance was sampled nonuniformly, the impedance
13 measurements in some gaps were not adequately sampled. To overcome this difficulty, we
14 uniformly resampled the impedance measurements (MATLAB function *resample* with linear
15 interpolation) to 24 samples per day before curve fitting. We used the coefficient of determination
16 (R^2) as an indicator of goodness-of-fit (GOF), and only included measures of $t_{1/2}$ from fittings
17 with $R^2 \geq 0.85$ in further analyses.

18 **Statistics of long-term impedance change in gaps**

19 We adopted the generalized estimating equation (GEE) method, as suggested in a previous study
20 on chronic impedance measurement of a neuromodulation system [7], to estimate the confidence
21 intervals of the time course of long-term impedance variation during stimulation gaps. As an
22 extension of the generalized linear model (GLM), the GEE is suitable for modeling data with high
23 correlation due to repeated measurements and missing data [26]. In our analysis, we followed the

1 paradigm suggested in [7], using binned time intervals as independent variables. The estimation
2 was implemented with the GEEQBox MATLAB toolbox [27] using an identity link, assuming a
3 normal distribution and AR(1) correlation structure. Statistical significance was defined as $p <$
4 0.01.

5 **Amplitude and phase of 24-hour circle**

6 To assess the stability of the amplitude and phase of 24-hour circle of effective impedance over
7 time, we partitioned the impedance recording into valid segments. These segments must meet
8 three criteria: (1) at least 3 weeks after device implantation, (2) a minimum duration of 5 days, and
9 (3) at least 40 impedance samples available. The segments were smoothed by resampling the
10 impedance measurements to 24 samples per day (see above for the method). We then applied a
11 Fast Fourier Transform (FFT) to obtain the amplitude and phase of the 24-hour cycle of mean-
12 subtracted impedance in each segment. The estimated amplitudes and phases were grouped every
13 100 days, with median and boxplot obtained for each 100-day segment. Phase refers to the relative
14 time of the peak of circadian cycle from midnight (12 am), with a phase of 12 pm, for instance,
15 indicating that the peak of the circadian cycle occurs at 12 pm (corresponding to 180°).

16

17 **Results**

18 We collected impedance measurements for approximately 1579 days, with a median of 285 days
19 and a range of 124 to 694 days. The average number of impedance samples per day varied between
20 33.13 and 239.99 (Table 1). Note that during the recording periods, most seizures occurred in the
21 left hemisphere, with the percentage of left seizures being 98.71% for S1, 99.20% for S2, 58.93%
22 for S3, 100% for S4, and 86.58% for S5.

1 **Significant difference of characteristic measures between left and right hemisphere** 2 **in initial impedance change**

3 The initial impedance change, which includes acute followed by subacute phase, showed typical
4 biphasic dynamics across all electrodes and subjects. This was characterized by a rapid drop
5 followed by a slower recovery to a stable state, as shown in Figure 2. We fitted the change to a
6 piecewise function, as described by Equation (1) (Figure 2A). We additionally compared it with
7 an alternative model of double exponential, Equation (4), at individual electrode level (Figure
8 2C). Overall, the piecewise model adequately represented the impedance change (Figure 2B and
9 C; S4 excluded) with an $R^2 = 0.89 \pm 0.21$ (Mean \pm SD, $n = 4$; see figure caption for sample size
10 at specific locations). After the implant of the device, the impedance reached its the minimum in
11 2.83 ± 0.63 days (Figure 3A). The time required was shorter in the right hemisphere (2.43 ± 0.39
12 days) than in the left hemisphere (3.32 ± 0.62 days) of THL (two-sample t -test assuming unequal
13 variance: $p < 0.001$, outliers excluded; see Figure 3 caption for sample size), but shorter in the left
14 hemisphere (2.37 ± 0.15 days) of AMG-HPC compared to the right (2.85 ± 0.31 days, $p < 0.01$).
15 No significant difference was found in post-HPC. The half-life measure (Figure 3B) of left THL
16 (2.92 ± 2.91 days) was longer than right THL (0.65 ± 0.66 days, $p < 0.01$). No significant
17 differences were found in AMG-HPC or post-HPC (all $p > 0.01$).

18 We defined impedance stability as an impedance rate-of-change (calculated as the first-order
19 derivative of the fitted exponential) of less than $\alpha = 5 \Omega/\text{day}$. We found that the time to reach
20 stability ($t_\alpha - t_1$, Figure 3C), where t_α is given by equation (2), was significantly longer in the
21 left hemisphere (17.17 ± 11.41 days) than in the right hemisphere (8.08 ± 2.88 days, $p < 0.01$). No
22 significant difference was found in the AMG-HPC or post-HPC structures (all $p > 0.01$). we also
23 examined the minimum impedance level (c_1) and the asymptotic level (c_2) (Figure 3D) and found
24 that only c_1 in the left THL ($667.58 \pm 109.83 \Omega$) was significantly lower than the right THL (815.63

1 $\pm 33.52 \Omega$, $p < 0.01$). No significant difference was found in the other structures for c_1 and no
2 difference was found in all structures for the asymptotic level c_2 .

3 The statistics related to THL were consistent across subjects and were not biased by individual
4 subjects (as shown in Supplementary Figure 1).

5 Taken together, these results suggest that, immediately after implantation during the acute and
6 subacute phases, the THL impedance in the more epileptogenic left hemisphere took a longer time
7 to decrease to a lower level than the less epileptogenic right hemisphere. However, it eventually
8 recovered to approximately the same level as the right hemisphere, albeit over a longer period.

9 **Impedance changes during gaps of therapeutic stimulation**

10 We identified 30, 5, 27, and 29 valid gaps (see Methods) in subjects S1-S4, respectively, as shown
11 in Figure 4 (S5 excluded). Due to the intermittent nature of the temporary pauses in stimulation,
12 the availability of impedance information during the gaps varied among the subjects (Table 2).
13 Figure 4A shows a typical time course of impedance rebound in the gaps close to an implant date.
14 The top row of Figure 3C displays the clusters of impedance changes per subject, as well as the
15 mean and 95% confidence interval (CI) of the impedance change as a function of time, estimated
16 by the GEE model in the stimulation channels. The impedance changes were larger when the gaps
17 were closer to the implant date. The data point of S1 at approximately 600 days indicated no
18 significant changes around that time. Furthermore, no clear correlation was observed between the
19 trend of impedance changes and stimulation conditions immediately before the gaps. This
20 contrasts with the measurements in the non-stimulation channels shown in the lower row of Panel
21 C, where no such impedance change trend was observed. We also conducted a control experiment
22 to assess the effect of the known growth process of a hydrous oxide layer on the iridium surface

1 [28] on the observed impedance difference (Figure 4A). The results suggest that the process was
2 unlikely to be responsible for this observation (see Discussion).

3 We further compared the estimated half-life values in the stimulation channels between those
4 estimated during the first three weeks post-implant (Figure 3B) and those in the stimulation gaps
5 (Figure 4B). It is important to note that neither therapeutic stimulation was applied in the first 3-
6 week period nor during the gaps, although stimulation was delivered before the gaps. In the right
7 hemisphere, which is the less epileptogenic brain region, the first 3-week half-life estimates were
8 significantly longer than those during the gaps (Right: 1st 3-week Mean \pm SD, 22.72 ± 15.25 hours;
9 gaps 1.92 ± 1.06 hours; two-sample *t*-test, $p = 0.01$). A similar trend was observed in the left
10 hemisphere electrodes, but with larger variance (Left: 1st 3-week 71.78 ± 68.69 hours; gaps $1.76 \pm$
11 0.94 hours; $p = 0.04$), suggesting that different mechanisms responsible for the increase in
12 impedance.

13 **Amplitude and phase of 24-hour cycle appear to be stable over extended periods.**

14 We analyzed the amplitude and phase of the long-term 24-hour cycle of impedance, as shown in
15 Figure 5 (also Supplementary Figure 3; see Methods for subjects involved in this analysis). Figure
16 5A displays the amplitude over the observed recording periods on both sides of THL, AMG-HPC,
17 and post-HPC. The amplitude varied across the subjects, with S1 having a significantly higher
18 amplitude than S2, S3, and S4 in all areas except for the left THL. However, for each individual
19 subject, the amplitude appeared to remain stable throughout the entire observation period. No
20 significant difference was found within the subjects (Wilcoxon rank sum test: all $p > 0.01$,
21 Bonferroni corrected).

22 Regarding the phase values shown in Figure 5B, we observed a similar pattern to that of amplitude.
23 The phase of the circadian cycle remained stable over the observation period, although it varied

1 across different anatomic locations. At THL, the phase values of all subjects did not significantly
2 deviate from 12 am, indicating that the maximum impedance of the 24-hour cycle occurred around
3 midnight. However, the time of maximum impedance differed among the hippocampal structures.
4 Except for S4 left AMG-HPC, which was approximately 12 am and significantly different from
5 S1 and S2, the phase values of S1 and S3 in the left AMG-HPC and of all subjects in other
6 hippocampal structures did not significantly deviate from 6 pm (Wilcoxon rank sum test: all $p >$
7 0.01 , Bonferroni corrected), indicating that their maximum amplitudes were around 6 pm, about 6
8 hours ahead of those in the thalamus. Supplementary Figure 3 further illustrates the relationship
9 between measured impedance and sleep/awake states. The two-day impedance measurements
10 display an approximate 24-hour cycle, with most Awake states occurring when impedance was
11 higher and most Sleep states occurring when impedance was lower. This is consistent with the
12 reports using animals [18].

13

14 Discussion

15 In this study, we sought to characterize impedance changes in both short-term (in the first 3 weeks
16 post-implant) and long-term (124 – 694 days) periods in human subjects. We developed a
17 piecewise function to describe the biphasic dynamics of the initial acute to subacute impedance
18 response. Our results suggest that the left and right THL exhibited distinct impedance change
19 dynamics immediately after implantation. The analyses of impedance behavior during the
20 temporal pauses of stimulation indicated an interaction between the stimulation and the tissues
21 near the electrodes and suggested that tissue encapsulation around the electrodes matured at about
22 200-300 days post-implant. Finally, we found that the amplitude and phase of the prominent 24-

1 hour cycle of impedance were relatively stable in the long term, which is also important for sleep
2 behavior [8, 23] (see examples in Supplementary Figure 3).

3 **The model revealed differential dynamics of acute and subacute impedance** 4 **responses in the left and right hemispheres.**

5 The short-term change in impedance after lead implantation, characterized by a rapid decrease
6 followed by a slow increase, has been reported in previous studies [6, 7, 13]. The initial drop is
7 thought to result from an inflammatory response to injury trauma caused by the implant [13].
8 During the early phase of the body's inflammatory response to foreign materials, an increase in
9 vascular permeability leads to fluid accumulation [29], which in turn reduces the impedance
10 around the electrodes. However, the slow increase in impedance was likely due to the formation
11 of encapsulation layers near the electrodes. The specific morphology of the encapsulated tissue
12 depends on the surface texture, shape, and material of the implant. Changes in the chronic implant
13 tissue interface have been attributed to the growth of the fibrous tissue capsule [13, 30]. While the
14 pattern of the subacute response is well documented, we are not aware of other studies that have
15 investigated long-term properties with sufficient temporal impedance sampling to resolve the more
16 subtle changes that were revealed by the model (discussed below).

17 By fitting our piecewise model (see Methods), we were able to gain further insights into the
18 response and to provide possible means to compare the results from different studies. For example,
19 the stability of the impedance recovery is not well defined but can be suggested by setting a
20 threshold (in this case, 5 Ω /day) for the first-order derivative of the exponential function. Our
21 modeling results show that using Pt-Ir electrodes, the impedance reached a minimum value at
22 approximately 3 days post-implant (Figure 3A) in human subjects, which is close to 4 days of
23 resistivity measurement using silicon rubber and 2 days using epoxy arrays in cats [13]. The
24 impedance measurements during the first week after implantation in our data were consistently

1 lower than the stable values after 3 weeks, consistent with a previous report of human data from
2 NeuroPace RNS™ device, which showed impedance values in the first week were significantly
3 lower than the stabilized value at one-year post-implant [7]. These results may indicate that similar
4 time courses of adaptation correlated with the progressive development of fibrous tissue capsule
5 around the implants, leading to an increase in impedance/resistivity. This process may not be
6 strongly related to the species or electrode materials. Our data also show that the recovered
7 impedance could reach a stable level in approximately 3 weeks (Figure 3C), which is similar to
8 previous reports of approximately 3 [22] to 4 weeks [31] in rats, approximately 40 days in cats
9 [13], and approximately 4 weeks in humans [7].

10 However, previous studies [6, 7, 30] did not differentiate their measurements in relation to the
11 degree of epileptogenicity of the tissue and networks involved in the generation of seizures
12 (Supplementary Table 1). Our results indicate that, on average, the impedance in the THL in the
13 more epileptogenic brain network (left side) took longer to reach the minimum than the
14 contralateral, less epileptogenic side of the THL (right side), and a longer half-life and longer
15 period from the minimum to the stable level in the left than in the right side of the THL. No
16 significant differences were observed in the AMG-HPC and post-HPC areas (Figure 3A, B and
17 C). In the THL, the minimum impedance on the left side was significantly lower than that on the
18 right side, but not in the AMG-HPC and post-HPC areas (c_1 in Figure 3D). No significant
19 difference was observed at a stable level (c_2 in Figure 3D) in any area. It appears that the observed
20 longer time needed to reach the minimum in the more epileptogenic left THL is mainly due to the
21 lower minimum impedance level, as no significant difference in rate of impedance decrease was
22 found between the left and right hemispheres (see Supplementary Figure 2).

1 The reason for the difference in acute-to-subacute impedance changes between the left and right
2 THL cannot be directly determined with these data. However, for our subjects, the left hemisphere
3 limbic networks were more highly epileptogenic, with significantly more interictal epileptiform
4 activity, seizures, and more severe delta frequency (Table 1 and Supplementary Table 1).
5 Interestingly, previous studies have argued that the cell types and structure of the encapsulated
6 tissue are largely independent of the site of electrode implantation [13]. If this is true, we speculate
7 that the difference observed during the first 3 weeks post-implant may be related to the pathology
8 of brain tissue in epilepsy, which is known to exhibit significant immunologic dysregulation [32-
9 35]. Impedance changes immediately around seizure spread have been well described [19, 36,
10 37], but little is known about the interictal impedance characteristics of the epileptic brain. Our
11 findings provide additional evidence and insights into this area of research, which warrants further
12 investigation.

13 **Analyses of gap impedance indicate maturity of encapsulation layers about 200-300**
14 **days post-implant.**

15 Intermittent gaps in therapeutic stimulation were present in the recordings for clinical purposes.
16 These gaps provided time windows for checking the impedance characteristics around and within
17 the gaps in electrical stimulation. Our results show that significant rebounds of impedance, from
18 lower values when electrical stimulation is active to progressively higher values after stimulation
19 is turned off, can be observed within approximately 300 days after implantation in the THL
20 electrodes used for stimulation (Figure 4C upper row). As shown in Figure 4A, the control
21 experiment suggested potential interactions between the stimulation and the electrode-tissue
22 interface. The observation likely reflects the previously reported phenomena where voltage
23 applied to the microelectrodes reduces the impedance by “cleaning” the electrode of biological
24 material. The impedance may be further effected by elevated blood flow, as neuronal hyperactivity

1 due to stimulation may increase blood perfusion around the electrodes [38]. Therefore, impedance
2 recovery during the stimulation gaps may be facilitated by decreased metabolic demands and blood
3 perfusion in brain tissue.

4 Our results suggest that, at least for clinical macroelectrodes, the growth of fibrous capsulation
5 tissue around the electrodes is less dynamic after ~300 days. The phenomenon of decreasing
6 impedance with voltage biasing (i.e., passing currents) may no longer be viable after ~1 year. For
7 functionally encapsulated microelectrode sites, it is possible to increase transient conductivity
8 pathways through the encapsulation of tissues by applying a DC bias voltage (typically +1.5 V) to
9 the electrode site for several seconds, known as the “rejuvenation” approach [24, 39]. However,
10 we speculate that the window for this phenomenon for the microelectrodes used to record single
11 neurons [24] is likely earlier and may not be viable for chronic implants.

12 The therapeutic neurostimulation used in our study was delivered as a counter-balanced square
13 wave pulse (typically with a frequency of 2 Hz, amplitude of 3.5 mA, and pulse-width of 200 μ s)
14 for extended period (days to weeks). It is not clear to what extent the stimulation might be able to
15 create transient conductivity pathways that lower impedance. However, given that no significant
16 rebound was found in non-stimulation channels in THL (Figure 4C, lower row), AMG-HPC, or
17 post-HPC (data not shown), it is likely that therapeutic stimulation was able to increase
18 conductivity pathways through encapsulation, particularly in the early period after implantation.
19 After 200-300 days of implantation, with the continuous growth of encapsulated tissue, the
20 creation of conductive pathways could not be established, and the efficacy of tissue stimulation
21 largely diminished. As a result, no significant impedance rebound was observed during the gaps,
22 indicating the maturity of fibrous encapsulation.

1 Further analysis revealed that the estimated half-life values in the gaps (1-2 hours) were
2 significantly shorter than those estimated in the first 3 weeks (several days, Figure 4B). These
3 results suggest that different mechanisms and stages of the encapsulation processes may be
4 responsible for the increase in impedance. Our findings may be useful in guiding the delivery of
5 therapeutic stimulation at various times post-implant.

6 **Long-term stability of 24-hour cycle of impedance**

7 One challenge of chronically implanted neuromodulation devices is the progressive development
8 of encapsulation layers around the electrodes, which can sometimes electrically shield an electrode
9 from the surrounding tissues, affecting the LFP sensing and therapeutic efficacy of
10 neuromodulation. This condition may be monitored by periodic impedance measurement, and
11 some previous studies with very sparse sampling of impedance have reported that impedance is
12 largely stable over long-term follow-up [6, 7]. In this study, we densely sampled impedance and
13 examined the stability of long-term impedance from a novel perspective by studying the stability
14 of the amplitude and phase of the circadian cycle of brain impedance.

15 It has been recently shown that 24-hour cycle of the effective impedance is a prominent feature
16 with little variation in periodicity over the duration of recording [23]. However, variations in the
17 amplitude and phase of the circadian impedance cycle have not been fully investigated. This is
18 important because the effect of the changes of bulk tissue (brain matter and encapsulation tissue)
19 near the electrodes may not have a major influence on the periodicity of the cycle, but rather on
20 the properties of electrical impedance, which are reflected by the variation in the amplitude and
21 phase. Our results showed that the amplitude and phase were stable within the subject over the
22 long-term recording period. Since the circadian cycle is thought to be related to variations in
23 extracellular space volume associated with the sleep-wake cycle [21, 23], the stability of amplitude

1 and phase suggests that the impedance variation due to the growth of encapsulation layers in the
2 immediate vicinity of the electrodes was substantially smaller than that due to the circadian cycle.
3 Therefore, when evaluating controlled stimulation design or tissue-electrode interface properties
4 by analyzing impedance measurements, it is recommended to preprocess the data by removing the
5 circadian component.

6 **Limitations of this study**

7 A major limitation of our study is the technical challenge of clearly differentiating between the
8 impedance of the electrode-tissue (i.e., electrode-electrolyte) interface and that of bulk tissue,
9 which includes brain matter and encapsulation layers (if formed), due to the use of two-point
10 impedance measurement. We recently investigated the differences between 4-point and two-point
11 method in saline and saline-microbead composite materials (Figure 1; also see Methods in [23]).
12 Our results show that the measured impedance with Medtronic Summit RC+S™ is insensitive to
13 the impedance of electrode-tissue interface. Therefore, we attribute the observed impedance
14 dynamics mainly to changes in bulk tissue near the electrodes. Furthermore, our observed half-
15 life values of acute-to-subacute impedance change after implantation (Figure 3), impedance
16 change during stimulation gaps (Figure 4), and relatively stable circadian impedance cycle
17 (Figure 5) indicate that changes in electrode-tissue interface impedance are unlikely to be the main
18 cause of the observed dynamics.

19 There are several other limitations to this study that should be noted. First, all the patients in our
20 study had drug-resistant mesial temporal lobe epilepsy, and our results may reflect the response of
21 the epileptogenic brain and may not be applicable to other neurological and psychological
22 disorders treated with electrical brain stimulation (EBS). It is notable that there was a difference
23 between the left and right hemispheres, which may reflect the greater epileptogenicity (tendency

1 of seizures and interictal epileptiform discharges, IED) of the left hemisphere in these subjects.
2 Second, the etiologies and functional and structural imaging findings of the patients were
3 heterogeneous, which may impact impedance. Additionally, they were taking different anti-
4 seizure medications that may affect brain impedance. Where possible, medications remained fixed
5 in this study. Third, the targeting of the electrodes is accurate to approximately 2-3 mm. The
6 impact of the imaging resolution of brain substructures and nuclei on impedance measurements
7 cannot be ascertained with the current data. Finally, we did not directly investigate the impact of
8 seizures and IED on impedance, which is an area of current investigation.

9

10 Conclusion

11 Characterizing the full dynamics of impedance is important for understanding its impact on LFP
12 sensing, therapeutic electrical stimulation, and for ensuring efficient and stable electrical brain
13 stimulation. In this study, we densely sampled the impedance and developed novel approaches for
14 analyzing the time course of the impedance response from the acute (1-3 days) to subacute (4–3
15 weeks) and long-term (> 3 weeks) stages.

16 For short-term (acute and subacute) changes in impedance, our results largely support the previous
17 findings. We further characterize the impedance response by fitting a piecewise function, where
18 a parabolic captures the drop and initial rebound phase and an exponential to approximate the later
19 asymptotic phase of the impedance. This descriptive model may be useful for comparing the
20 results from different experiments. It is worth noting that, according to the estimates from the
21 model, significant differences in characteristics between the left and right THL are present. We
22 speculate that this reflects the more epileptogenic left hemisphere limbic network and AMG-HPC

1 structure. Given the dominant left seizures in our subjects, these findings may have implications
2 for the pathological effect on short-term impedance dynamics, which requires further
3 investigation.

4 In our investigation of long-term impedance measures, we found significant impedance rebound
5 during the temporary gaps of the stimulus, consistent with other studies. However, our results
6 further suggested that the degree of rebound decreased over time and was no longer observable
7 between 200 and 300 days after implantation, indicating possible maturity of encapsulation by
8 fibrous tissues around the electrodes. We also propose a novel perspective on long-term
9 impedance by examining the stability of the amplitude and phase of the prominent circadian cycle
10 of impedance. Our findings suggest not only that the amplitude and phase were relatively stable
11 over time, but also that the daily variance was dominant in impedance changes.

12

13 Acknowledgments

14 We thank Irena Balzekas, Victoria S. Marks PhD, Jordan S. Clark MS, Andrea M. Duque Lopez
15 MD, and Dalia Zubidat MD for their thoughtful discussions during this study and preparation of
16 the manuscript.

17 Conflict of Interest

18 **G.A.W., B.H.B., J.V.G., and B.N.L.** are inventors of intellectual property developed at Mayo
19 Clinic and licensed to Cadence Neuroscience Inc. The intellectual property for impedance
20 modulation and tracking was filed by **G.A.W., V.K., V.S., and B.H.B.** **G.A.W.** has also licensed
21 intellectual property developed at Mayo Clinic to NeuroOne Inc. **B.N.L., G.A.W., J.V.G., and**

1 **N.G.** are investigators in the Medtronic Deep Brain Stimulation Therapy for Epilepsy Post-
2 Approval Study (EPAS). Mayo Clinic has received research support and consulting fees on behalf
3 of **G.A.W.**, **B.N.L.**, **J.V.G.**, and **B.H.B.** from UNEEG, NeuroOne Inc., Epiminder, Medtronic Plc.,
4 and Philips Neuro. **J.V.G.** is a stock owner of NeuroOne Inc and the site Primary Investigator in
5 the Polyganics ENCASE II trial, the NXDC Gleolan Men301 trial, and the Insightec MRgUS
6 EP001 trail. **T.D.** is a consultant for Synchron, a member of the advisory board of Cortec Neuro,
7 and a shareholder-collaborator of Bioinduction Ltd and shareholder director of Amber
8 Therapeutics Ltd. **T.D.** also has patents in the field of impedance measurement instrumentation
9 and its application in epilepsy seizure prediction. **B.N.L.** declares intellectual property licensed to
10 Cadence Neuroscience Inc (contractual rights waived; all funds to Mayo Clinic) and Seer Medical
11 Inc (contractual rights waived; all funds to Mayo Clinic), is a site investigator for Medtronic EPAS
12 and Neuroelectrics tDCS for Epilepsy, and an industry consultant for Epiminder, Medtronic,
13 Neuropace, and Philips Neuro (all funds to Mayo Clinic). The other authors have no disclosures.

14 Data accessibility

15 Data are available upon reasonable request to the authors.

16 Fundings

17 National Institutes of Health (NIH) supported this study by grants UH3-NS095495, R01-
18 NS092882 (to G.W.), and R01-NS112144 (to G.W., H.L.W., and L.J.W.). J.C. was also partially
19 supported by the Epilepsy Foundation of America's My Seizure Gauge grant (to B.H.B), the
20 National Institutes of Health grant UG3 NS123066 (to B.H.B.), and the Mayo Clinic RFA CCaTS-
21 CBD Pilot Awards for Team Science UL1TR000135 (to J.C.).

1 Appendix

2 A. Estimate model parameters and time of stability of subacute impedance change.

3 We estimated the model parameters of Equation (1) using the nonlinear least-squares algorithm
4 (MATLAB[®] Function *fit*). To fit the model, we assume that $Z(t)$ and its first-order derivative
5 $Z'(t)$ are continuous at node t_0 , the boundary of the parabolic function, and the exponential
6 function, that is,

$$Z'(t) = \begin{cases} 2a_1(t - t_1) & \text{for } t < t_0 \\ \frac{a_2}{\tau} e^{-(t-t_2)/\tau} & \text{for } t \geq t_0, \end{cases} \quad (5)$$

7 and

$$\begin{cases} Z(t_0^-) = Z(t_0^+) \\ Z'(t_0^-) = Z'(t_0^+), \end{cases} \quad (6)$$

8 which gives us the relations of t_0 and a_2 with other parameters,

$$t_0 = t_1 + \tau \left(\sqrt{1 + (c_2 - c_1) \left(\frac{1}{a_1 \tau} \right)^2} - 1 \right), \quad (7)$$

9 and

$$a_2 = 2a_1^2 \tau (t_0 - t_1) e^{(t_0 - t_2)/\tau}. \quad (8)$$

10 Thus, six parameters, $a_1, t_1, t_2, c_1, c_2, \tau \in \mathbb{R}^+$ were estimated from the model fitting. The initial
11 values of these parameters are presented in Supplementary Table 2.

12 From Equation (3), if we define that $Z(t)$ is stable when its change rate is below a threshold α ,
13 i.e., $Z'(t_\alpha) \leq \alpha$ for $t \geq t_0$, then we can find the start time of stable $Z(t)$ shown in Equation (2).

14 In practice, α was arbitrarily set to 5 Ω/day .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

References

- [1] J. P. Cook and J. I. Ausman, "New features in surgical neurology international for 2013," (in eng), *Surg Neurol Int*, vol. 4, p. 33, 2013, doi: 10.4103/2152-7806.109510.
- [2] V. Sladky *et al.*, "Distributed brain co-processor for tracking spikes, seizures and behaviour during electrical brain stimulation," *Brain Communications*, vol. 4, no. 3, p. fcac115, 2022/06/01/ 2022, doi: 10.1093/braincomms/fcac115.
- [3] N. M. Gregg *et al.*, "Thalamic deep brain stimulation modulates cycles of seizure risk in epilepsy," (in en), *Sci Rep*, vol. 11, no. 1, p. 24250, 2021/12/20/ 2021, doi: 10.1038/s41598-021-03555-7.
- [4] V. Kremen *et al.*, "Integrating Brain Implants With Local and Distributed Computing Devices: A Next Generation Epilepsy Management System," *IEEE Journal of Translational Engineering in Health and Medicine*, vol. 6, pp. 1-12, 2018 2018, doi: 10.1109/JTEHM.2018.2869398.
- [5] R. e. Gilron *et al.*, "Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease," (in en), *Nat Biotechnol*, vol. 39, no. 9, pp. 1078-1085, 2021/09// 2021, doi: 10.1038/s41587-021-00897-5.
- [6] K. A. Sillay *et al.*, "Long-Term Surface Electrode Impedance Recordings Associated with Gliosis for a Closed-Loop Neurostimulation Device," (in english), *AON*, vol. 25, no. 4, pp. 289-298, 2018 2018, doi: 10.1159/000481805.
- [7] K. A. Sillay *et al.*, "Long-Term Measurement of Impedance in Chronically Implanted Depth and Subdural Electrodes During Responsive Neurostimulation in Humans," (in en),

- 1 *Brain Stimulation*, vol. 6, no. 5, pp. 718-726, 2013/09/01/ 2013, doi:
2 10.1016/j.brs.2013.02.001.
- 3 [8] F. Mivalt *et al.*, "Electrical brain stimulation and continuous behavioral state tracking in
4 ambulatory humans," (in en), *J. Neural Eng.*, vol. 19, no. 1, p. 016019, 2022/02// 2022,
5 doi: 10.1088/1741-2552/ac4bfd.
- 6 [9] A. Prasad and J. C. Sanchez, "Quantifying long-term microelectrode array functionality
7 using chronic in vivo impedance testing," (in en), *J. Neural Eng.*, vol. 9, no. 2, p. 026028,
8 2012/03// 2012, doi: 10.1088/1741-2560/9/2/026028.
- 9 [10] J. P. Frampton, M. R. Hynd, M. L. Shuler, and W. Shain, "Effects of Glial Cells on
10 Electrode Impedance Recorded from Neural Prosthetic Devices In Vitro," (in en), *Annals*
11 *of Biomedical Engineering*, vol. 38, no. 3, pp. 1031-1047, 2010/03/01/ 2010, doi:
12 10.1007/s10439-010-9911-y.
- 13 [11] M. P. Ward, P. Rajdev, C. Ellison, and P. P. Irazoqui, "Toward a comparison of
14 microelectrodes for acute and chronic recordings," (in en), *Brain Research*, vol. 1282, pp.
15 183-200, 2009/07/28/ 2009, doi: 10.1016/j.brainres.2009.05.052.
- 16 [12] N. K. Logothetis, C. Kayser, and A. Oeltermann, "In Vivo Measurement of Cortical
17 Impedance Spectrum in Monkeys: Implications for Signal Propagation," (in en), *Neuron*,
18 vol. 55, no. 5, pp. 809-823, 2007/09/06/ 2007, doi: 10.1016/j.neuron.2007.07.027.
- 19 [13] W. M. Grill and J. Thomas Mortimer, "Electrical properties of implant encapsulation
20 tissue," (in en), *Ann Biomed Eng*, vol. 22, no. 1, pp. 23-33, 1994/01/01/ 1994, doi:
21 10.1007/BF02368219.
- 22 [14] G. Cascino, J. I. Sirven, and W. O. Tatum, *Epilepsy*, Second edition. ed. Hoboken, NJ:
23 Wiley-Blackwell, 2020, p. pages cm.

- 1 [15] J. L. Noebels and H. H. Jasper, *Jasper's basic mechanisms of the epilepsies*, 4th ed.
2 (Contemporary neurology series, no. 80). New York: Oxford University Press, 2012, pp.
3 lvii, 1199 p.
- 4 [16] J. B. Ranck, "Analysis of specific impedance of rabbit cerebral cortex," (in en),
5 *Experimental Neurology*, vol. 7, no. 2, pp. 153-174, 1963/02/01/ 1963, doi:
6 10.1016/S0014-4886(63)80006-0.
- 7 [17] J. B. Ranck, "Specific impedance of rabbit cerebral cortex," (in en), *Experimental*
8 *Neurology*, vol. 7, no. 2, pp. 144-152, 1963/02/01/ 1963, doi: 10.1016/S0014-
9 4886(63)80005-9.
- 10 [18] L. Xie *et al.*, "Sleep Drives Metabolite Clearance from the Adult Brain," *Science*, vol. 342,
11 no. 6156, pp. 373-377, 2013/10/18/ 2013, doi: 10.1126/science.1241224.
- 12 [19] Z. Elazar, R. T. Kado, and W. R. Adey, "Impedance Changes during Epileptic Seizures,"
13 (in en), *Epilepsia*, vol. 7, no. 4, pp. 291-307, 1966 1966, doi: 10.1111/j.1528-
14 1157.1966.tb03809.x.
- 15 [20] A. Van Harreveld and J. P. Schadé, "Changes in the electrical conductivity of cerebral
16 cortex during seizure activity," (in en), *Experimental Neurology*, vol. 5, no. 5, pp. 383-400,
17 1962/05/01/ 1962, doi: 10.1016/0014-4886(62)90051-1.
- 18 [21] J. B. Ranck, "Electrical impedance in the subicular area of rats during paradoxical sleep,"
19 (in en), *Experimental Neurology*, vol. 16, no. 4, pp. 416-437, 1966/12/01/ 1966, doi:
20 10.1016/0014-4886(66)90107-5.
- 21 [22] J. B. Ranck, "Electrical impedance changes in many sites of brain in paradoxical sleep,
22 anesthesia, and activity," (in en), *Experimental Neurology*, vol. 27, no. 3, pp. 454-475,
23 1970/06/01/ 1970, doi: 10.1016/0014-4886(70)90107-X.

- 1 [23] F. Mivalt *et al.*, "Impedance Rhythms in Human Limbic System," (in en), *Journal of*
2 *Neuroscience*, vol. 43, no. 39, pp. 6653-6666, 2023/09/27/ 2023, doi:
3 10.1523/JNEUROSCI.0241-23.2023.
- 4 [24] M. D. Johnson, K. J. Otto, and D. R. Kipke, "Repeated voltage biasing improves unit
5 recordings by reducing resistive tissue impedances," *IEEE Transactions on Neural Systems*
6 *and Rehabilitation Engineering*, vol. 13, no. 2, pp. 160-165, 2005/06// 2005, doi:
7 10.1109/TNSRE.2005.847373.
- 8 [25] B. Krishnamachari, R. Bejar, and S. Wicker, "Distributed problem solving and the
9 boundaries of self-configuration in multi-hop wireless networks," in *Proceedings of the*
10 *35th Annual Hawaii International Conference on System Sciences*, 2002/01// 2002, pp.
11 3856-3865, doi: 10.1109/HICSS.2002.994520. [Online]. Available:
12 <https://ieeexplore.ieee.org/document/994520>
- 13 [26] S. L. Zeger and K.-Y. Liang, "Longitudinal Data Analysis for Discrete and Continuous
14 Outcomes," *Biometrics*, vol. 42, no. 1, pp. 121-130, 1986 1986, doi: 10.2307/2531248.
- 15 [27] S. J. Ratcliffe and J. Shults, "GEEQBOX: A MATLAB Toolbox for Generalized
16 Estimating Equations and Quasi-Least Squares," (in en), *Journal of Statistical Software*,
17 vol. 25, pp. 1-14, 2008/05/01/ 2008, doi: 10.18637/jss.v025.i14.
- 18 [28] L. S. Robblee, J. L. Lefko, and S. B. Brummer, "Activated Ir: An Electrode Suitable for
19 Reversible Charge Injection in Saline Solution," (in en), *J. Electrochem. Soc.*, vol. 130, no.
20 3, p. 731, 1983/03/01/ 1983, doi: 10.1149/1.2119793.
- 21 [29] J. M. Anderson, "Biological Responses to Materials," *Annual Review of Materials*
22 *Research*, vol. 31, no. 1, pp. 81-110, 2001 2001, doi: 10.1146/annurev.matsci.31.1.81.

- 1 [30] W. M. Grill, S. E. Norman, and R. V. Bellamkonda, "Implanted Neural Interfaces:
2 Biochallenges and Engineered Solutions," *Annual Review of Biomedical Engineering*, vol.
3 11, no. 1, pp. 1-24, 2009 2009, doi: 10.1146/annurev-bioeng-061008-124927.
- 4 [31] S. Wurth *et al.*, "Long-term usability and bio-integration of polyimide-based intra-neural
5 stimulating electrodes," (in en), *Biomaterials*, vol. 122, pp. 114-129, 2017/04/01/ 2017,
6 doi: 10.1016/j.biomaterials.2017.01.014.
- 7 [32] D. B. Bosco, D.-S. Tian, and L.-J. Wu, "Neuroimmune interaction in seizures and epilepsy:
8 focusing on monocyte infiltration," (in en), *The FEBS Journal*, vol. 287, no. 22, pp. 4822-
9 4837, 2020 2020, doi: 10.1111/febs.15428.
- 10 [33] L. Feng *et al.*, "Microglial proliferation and monocyte infiltration contribute to microgliosis
11 following status epilepticus," (in en), *Glia*, vol. 67, no. 8, pp. 1434-1448, 2019 2019, doi:
12 10.1002/glia.23616.
- 13 [34] A. Vezzani, J. French, T. Bartfai, and T. Z. Baram, "The role of inflammation in epilepsy,"
14 (in en), *Nat Rev Neurol*, vol. 7, no. 1, pp. 31-40, 2011/01// 2011, doi:
15 10.1038/nrneurol.2010.178.
- 16 [35] A. Vezzani and T. Granata, "Brain Inflammation in Epilepsy: Experimental and Clinical
17 Evidence," (in en), *Epilepsia*, vol. 46, no. 11, pp. 1724-1743, 2005 2005, doi:
18 10.1111/j.1528-1167.2005.00298.x.
- 19 [36] M. Broberg, K. J. Pope, T. Lewis, T. Olsson, M. Nilsson, and J. O. Willoughby, "Cell
20 swelling precedes seizures induced by inhibition of astrocytic metabolism," (in en),
21 *Epilepsy Research*, vol. 80, no. 2, pp. 132-141, 2008/08/01/ 2008, doi:
22 10.1016/j.eplepsyres.2008.03.012.

- 1 [37] I. Dietzel, U. Heinemann, G. Hofmeier, and H. D. Lux, "Transient changes in the size of
2 the extracellular space in the sensorimotor cortex of cats in relation to stimulus-induced
3 changes in potassium concentration," (in en), *Exp Brain Res*, vol. 40, no. 4, pp. 432-439,
4 1980/11/01/ 1980, doi: 10.1007/BF00236151.
- 5 [38] R. Chaney, P. Garnier, A. Quirié, A. Martin, A. Prigent-Tessier, and C. Marie, "Region-
6 Dependent Increase of Cerebral Blood Flow During Electrically Induced Contraction of
7 the Hindlimbs in Rats," *Frontiers in Physiology*, vol. 13, 2022 2022. [Online]. Available:
8 <https://www.frontiersin.org/articles/10.3389/fphys.2022.811118>.
- 9 [39] K. J. Otto, M. D. Johnson, and D. R. Kipke, "Voltage pulses change neural interface
10 properties and improve unit recordings with chronically implanted microelectrodes," *IEEE*
11 *Transactions on Biomedical Engineering*, vol. 53, no. 2, pp. 333-340, 2006/02// 2006, doi:
12 10.1109/TBME.2005.862530.
- 13

1 Figures

2 Figure captions

3

4 **Figure 1.** Impedance measurement. (A) The investigational Medtronic RC+S™ is a
5 rechargeable device that enables 16 electrode contact electrical stimulation and programmable 4
6 LFP sensing channels from bipolar electrode contact pairs. (B) Lateral x-ray after implantation of
7 the bilateral ANT (3387-leads) and bilateral AMG-HPC (3391-lead) targets. The lead extensions
8 are tunneled down the neck to the sub-clavicular device pocket. The 3391-lead has four contacts
9 (surface area = 11.97 mm²) spanning 24.5 mm. The contacts are 3.0 mm long and separated by
10 4.0 mm. The 3387-lead has four contacts (contact surface area = 5.985 mm²) spanning 10.5 mm.
11 The individual contacts are 1.5 mm long and separated by 1.5 mm. (C) Schematic diagrams of the
12 microenvironment of the electrode and brain tissue (a) and the corresponding model using
13 saline/microbead composites (b) for benchtop experiment. The 2-point measurement employs the
14 same electrodes contacts (E1 & E2) for both electrical stimulation and voltage sensing. The 4-
15 point impedance measurement uses different electrodes for stimulation (E1 & E4) and sensing (E2
16 & E3). The 4-point measurements eliminate the interface electrode-electrolyte polarization,
17 related to electrical stimulation, from the voltage measurements. (D) The RC+S™ calculates 2-
18 point impedance using Ohm's law, $Z = V/I$, where I is the injected current (0.4 mA, 80 μs pulse
19 width) and V is the voltage response measured at 70 μsec. The voltage recording using 2-point
20 measurement shows the voltage response to the impulse current (0.4 mA, 80 μs pulse width) with
21 charging of the electrode-electrolyte double layer capacitor, which reaches an asymptotic voltage
22 within ~50 μs. (E) Impedance measured using sinusoidal currents in saline/microbead composites
23 (1 – 5000 Hz). The 2-point measurements are dominated at low frequency (< 500 Hz) by the

1 frequency dependent capacitive double-layer related to the electrolyte polarization at the electrode-
2 electrolyte interface. The 4-point impedance measurement, utilizing different electrodes for
3 current injection and voltage response sensing, yields a purely resistive impedance with no
4 frequency dependence (10 – 5000 Hz). The RC+STM impedance measurement (blue dashed line)
5 can be seen to correlate with ~1000 Hz sinusoidal current input.

6 **Figure 2.** Fitting the model to the impedance change in the first three weeks post-implant (S1, S2,
7 S3 and S5). **(A)** The measured effective impedance values (Z) were fitted with a piecewise
8 function consisting of a parabolic and an exponential function, Equation (1). The light purple
9 dots show the sampled impedance measures. The orange curve indicates the fitted parabolic
10 function, while the brown curve the fitted exponential function. t_1 is the time when the fitted
11 function is at the minimum c_1 , t_0 the boundary between the functions and t_α the time when the
12 impedance is supposed to be at stable state (see Methods and Appendix). We define the time to
13 reach stability as the time elapsed from t_1 to t_α , i.e., $t_\alpha - t_1$. c_2 is the asymptotic level of the
14 fitted exponential. Note that half-life $t_{1/2}$ is relative to the boundary t_0 . **(B)** Boxplots of R^2
15 (goodness-of-fit, GOF) of the model fits of all individual channels shown in (C) (sample size N of
16 THL: [$N_{\text{left}} = 16$, $N_{\text{right}} = 16$], AMG-HPC: [6, 8] and post-HPC: [10, 7]). **(C)** The raw impedance
17 measures and the fitted models at each individual channel (see Supplementary Table 3 for the
18 locations of the electrodes). The blue dots indicate the raw impedance, the red curves the fitted
19 piecewise model and the cyan curves the fitted double exponential model. Arrows indicate
20 apparent deficiency of the double exponential model. Note that subject S4 was excluded because
21 no impedance measurement was performed in the first 9 days after device implantation and
22 electrode EL_15 of S5 was disconnected after the implant. Abbreviation: **exp.**, exponential.

1 **Figure 3.** Characterization of acute to subacute impedance change post-implant (S1, S2, S3 and
2 S5). Boxplots of (A) time of minimum impedance (t_1) of the fitted models for all the available
3 electrodes from the three areas at left/right hemisphere (sample size N of THL: [$N_{\text{left}} = 16$, $N_{\text{right}} =$
4 15], AMG-HPC: [6, 8] and post-HPC: [9, 7]), (B) half-life ([16, 15], [5, 8], [9, 7]), (C) time from
5 the minimum impedance to reach stability ([16, 15], [5, 8], [7, 7]) and (D) the minimum (c_1 , [16,
6 14], [6, 8], [10, 6]) and asymptotic (c_2 , [16, 14], [6, 7], [10, 7]) impedance levels are shown. The
7 solid-colored boxes are for c_1 and the no-filled ones c_2 in (D). For all boxplots, the blue boxes
8 were from channels of the three anatomic areas at the left hemisphere and the orange ones at the
9 right hemisphere. Note that S4 was not included in this analysis (see Methods and Figure 1) and
10 that the sample size N involved in significant test excluded outliers (see Supplementary Table 3
11 for total sample size). Significance test: two-sample t -test assuming unequal variances, * $p < 0.01$,
12 ** $p < 0.001$; Abbreviation: THL, thalamus; AMG-HPC, amygdala-hippocampus; post-HPC,
13 posterior hippocampus; Min., Minimum; imp., impedance.

14 **Figure 4.** Characterization of impedance change during the gaps of therapeutic stimulation from
15 subjects S1 – S4. (A) An example of impedance changes *in vivo* and in saline. The 2-point
16 impedance was measured every two minutes from the electrodes EL_01 and EL_02 of a Summit
17 RC+STM device immersed in a body of physiological saline. The red solid and dashed lines
18 represent the measured impedance from these two electrodes (between 145 and 150 Ω , right axis).
19 The vertical solid green line indicates the termination of a stimulation (frequency: 2 Hz, amplitude:
20 3.5 mA, pulse-width: 200 μsec) delivered for > 5 hours, which was resumed after 8 hours
21 (indicated by the purple vertical solid line). As a comparison, the blue solid and dashed lines
22 represent the impedance values of the two electrodes targeting the left THL of subject S3, aligned
23 with those measured in the saline at stimulation offset ($t = 0$). The parameters of the stimulation

1 delivered in S3 were the same as those for the saline experiment, except that the therapeutic
2 stimulation resumed after ~9 hours (the dashed purple vertical line). We can see significant
3 rebound of impedance (with maximum around 1000 to 1060 Ω) in this specific gap (~70 days post-
4 implant). No such rebound can be seen in the impedance measures in the saline. (B) Impedance
5 changes relative to the impedance values prior to the gaps (sample size of gaps 30, 5, 27, 29; see
6 Methods for details). The upper row shows the impedance changes measured from the stimulation
7 electrodes targeted in left/right THL of the four subjects. The lower row the impedance changes
8 from the non-stimulation electrodes/channels in the THL. Each dot indicates the relative
9 impedance change of median values in a gap. The dashed lines indicate the mean impedance
10 rebound values estimated by the GEE model as a function of time, where the shaded areas indicate
11 the 95% CI around the mean. A tuple of parenthesized three values of frequency (Hz), amplitude
12 (mA) and pulse-width (μ sec) display the stimulation states immediately before the gaps. For
13 instance, a tuple of (2, 3.5, 200) indicates 2 Hz current pulse with 3.5 mA and 200 μ sec pulse-
14 width. (C) Boxplots of half-life measures from the stimulation electrodes. The blue plots show
15 the half-life measures of the fitted exponential functions for the impedance change in the first 3
16 weeks (21 days) after the implant and the orange plots the half-life measures of the fitted
17 exponential for the impedance in the gaps (sample size N of left: [first 21 days = 7, gaps = 108], N
18 of right: [7, 86]). Note that all measures are from the stimulation electrodes targeted in THL and
19 that subject S5 was not included in the analysis (see Methods). Abbreviations: THL, thalamus;
20 stim., stimulation, chan., channels; CI, confidence interval.


21 **Figure 5.** Long-term amplitude and phase of circadian cycles of impedance at THL, AMG-HPC
22 and post-HPC. (A) Amplitude and (B) phase of circadian cycle of left/right hemisphere. Boxplots
23 represent the distribution of the estimates (see Supplementary Table 4 for the number of samples) in

1 a 100-day interval for each subject. Note that scales vary between panels for amplitude and are
2 consistent for phase. S5 was excluded and no signals from left AMG-HPC structure of S2 (see
3 Methods). Abbreviations: SD, standard deviation; THL, thalamus; AMG-HPC, amygdala-
4 hippocampus; post-HPC, posterior hippocampus.

5

1 Figure 1

2




3

4


5

1 Figure 2
2




3
4

1 Figure 3
2



3
4
5



1 Figure 4
2



3
4

1 Figure 5

2



3

4

5

1 Tables

2 Table 1

3

4

Table 1. Summary of impedance recording and types of seizures

Subject	Days	Samples/Day	Sampling interval (min)	Left Sz	Right Sz	Both Sides Sz	Self-Rep. Sz	Total Number
S1	693.49	57.44	25.05 ± 126.45	537	1	5	1	544
S2	284.99	33.13	43.37 ± 289.76	3728	11	2	17	3758
S3	182.28	74.46	19.28 ± 32.53	66	45	1	0	112
S4	294.57	74.74	18.76 ± 84.97	39	0	0	0	39
S5	124.06	239.88	5.97 ± 45.37	129	19	1	0	149

5

Abbreviation: Sz, Seizure; Self-Rep., self-reported

6

1 Table 2

2

3 **Table 2.** Impedance changes during the gaps of therapeutic stimulation

Gap cluster		Channel	S1	S2	S3	S4
1	Time [day]		61.00	—	84.29	30.45
	Left imp. [Ω]	Stim.	186.25 \pm 163.07	—	136.59 \pm 39.65	606.50 \pm 68.59
		Non-Stim.	-7.33 \pm 26.14	—	8.77 \pm 22.40	-22.50 \pm 31.82
	Right imp. [Ω]	Stim.	192.08 \pm 87.39	—	140.37 \pm 38.00	627.00 \pm 70.71
		Non-Stim.	-53.92 \pm 97.07	—	-3.77 \pm 17.62	21.00 \pm 5.66
2	Time [day]		212.47	241.08	—	194.91
	Left imp. [Ω]	Stim.	-12.50 \pm 17.68	22.83 \pm 25.71	—	45.94 \pm 21.76
		Non-Stim.	16.00 \pm 79.20	-38.17 \pm 141.18	—	-0.64 \pm 37.54
	Right imp. [Ω]	Stim.	82.50 \pm 53.03	51.58 \pm 39.82	—	51.18 \pm 18.87
		Non-Stim.	97.00 \pm 56.57	11.67 \pm 44.07	—	3.99 \pm 26.16
3	Time [day]		594.47	—	—	—
	Left imp. [Ω]	Stim.	3.13 \pm 25.21	—	—	—
		Non-Stim.	14.91 \pm 56.50	—	—	—
	Right imp. [Ω]	Stim.	-3.66 \pm 13.51	—	—	—
		Non-Stim.	37.04 \pm 39.62	—	—	—

4 Note: mean \pm SD. Abbreviations: **imp.**, impedance; **stim.**, stimulation.

5